• Register
  • Login

Canadian Journal of Medicine

  1. Home
  2. Identification and Expression of GFAP, YKL-40 and RBP4 in Serum as Noninvasive Biomarkers with Diagnostic and Prognostic Value for Detecting and Monitoring Glioma Patients

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Related Links

FAQ

Aims and Scope

Editorial Board

Peer Review Process

Indexing and Abstracting

News

Identification and Expression of GFAP, YKL-40 and RBP4 in Serum as Noninvasive Biomarkers with Diagnostic and Prognostic Value for Detecting and Monitoring Glioma Patients

    Authors

    • Fawziah M. Mohammed 1
    • Nima Mohseni Kabir 2

    1 Department of Medical Laboratory Sciences. Faculty of Allied Health Sciences. Kuwait University, Kuwait

    2 MD, Neurosurgeon, Tehran, Iran

,
10.33844/cjm.2019.60488
  • Article Information
  • Download
  • Export Citation
  • Statistics
  • Share

Abstract

The prognosis of patients with malignant glioma is poor. Identification of novel and effective
biomarkers for this purpose has long been an important target. In this study, we investigated the role
and expression of GFAP, YKL-40 and RBP4 in glioma patients. We evaluated the expression of
markers above on glioma by ELISA, qRT-PCR, Western blot, Kaplan-Meier method, log-rank test
and Cox proportional-hazard analysis. The median RBP4 level in serum sample of patients was
53.61 ± 21.23 ng/ml, while it was 13.07 ± 10.31 ng/ml in control group. Moreover, the result
revealed raised serum concentrations of YKL-40 and GFAP in patients as compared to controls.
(The median level: 293.51± 105.41 versus 86.4 ± 51.2 ng/ml; 187.51± 91.06 versus 24.27 ±
12.64 ng/ml, respectively).And also, the transcriptional levels of RBP4 were determined to be
increased in tumor tissue samples compared with control samples (mean ± SD: 2.82 ± 1.23 vs. 0.75
± 0.21, P <0.001), as well as transcriptional levels YKL-40 and GFAP were notably strong in glioma
patients, comparable to that seen in control tissues (mean ± SD: 5.33± 1.13 vs. 1.21 ± 0.86; 3.05±
1.37 vs. 0.68 ± 0.34; all P <0.001). Consistent with the transcriptional levels, western blotting
analysis also indicated that the RBP4, YKL-40 and GFAP proteins were increased in glioma tissues.
Furthermore, the serum RBP4 level was not linked to advanced tumor grade, age, location or gender
or with Karnofsky performance Status (KPS) (all P >0.05). The serum YKL-40 and GFAP levels
were significantly higher in glioma patients with high tumor grades (P= 0.001). The Kaplan-Meier
analysis and the Log-rank test showed that high expression of YKL-40 and GFAP were associated
with shorter survival (All p <0.001), while RBP4 expression was not related to shorter survival (P
>0.05). Our results showed that high serum expression of YKL-40 and GFAP were independent
prognostic molecule biomarkers for poor prognosis prediction in glioma patients

Keywords

  • Glioma
  • PCR
  • Analysis
  • Marker
  • Expression
  • XML
  • PDF 1.13 M
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • CHICAGO
  • VANCOUVER
    • Article View: 439
    • PDF Download: 392
Canadian Journal of Medicine
Volume 1, Issue 1
January 2019
Page 10-19
Files
  • XML
  • PDF 1.13 M
Share
Export Citation
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • CHICAGO
  • VANCOUVER
Statistics
  • Article View: 439
  • PDF Download: 392

APA

M. Mohammed, F. and Mohseni Kabir, N. (2020). Identification and Expression of GFAP, YKL-40 and RBP4 in Serum as Noninvasive Biomarkers with Diagnostic and Prognostic Value for Detecting and Monitoring Glioma Patients. Canadian Journal of Medicine, 1(1), 10-19. doi: 10.33844/cjm.2019.60488

MLA

M. Mohammed, F. , and Mohseni Kabir, N. . "Identification and Expression of GFAP, YKL-40 and RBP4 in Serum as Noninvasive Biomarkers with Diagnostic and Prognostic Value for Detecting and Monitoring Glioma Patients", Canadian Journal of Medicine, 1, 1, 2020, 10-19. doi: 10.33844/cjm.2019.60488

HARVARD

M. Mohammed, F., Mohseni Kabir, N. (2020). 'Identification and Expression of GFAP, YKL-40 and RBP4 in Serum as Noninvasive Biomarkers with Diagnostic and Prognostic Value for Detecting and Monitoring Glioma Patients', Canadian Journal of Medicine, 1(1), pp. 10-19. doi: 10.33844/cjm.2019.60488

CHICAGO

F. M. Mohammed and N. Mohseni Kabir, "Identification and Expression of GFAP, YKL-40 and RBP4 in Serum as Noninvasive Biomarkers with Diagnostic and Prognostic Value for Detecting and Monitoring Glioma Patients," Canadian Journal of Medicine, 1 1 (2020): 10-19, doi: 10.33844/cjm.2019.60488

VANCOUVER

M. Mohammed, F., Mohseni Kabir, N. Identification and Expression of GFAP, YKL-40 and RBP4 in Serum as Noninvasive Biomarkers with Diagnostic and Prognostic Value for Detecting and Monitoring Glioma Patients. Canadian Journal of Medicine, 2020; 1(1): 10-19. doi: 10.33844/cjm.2019.60488

  • Home
  • About Journal
  • Editorial Board
  • Submit Manuscript
  • Contact Us
  • Sitemap

News

  • PubMed, a practical free resource for medical students 2022-05-23
  • Tips on rules of publishing articles in journals 2022-01-13
  • What is the BEST title for your research paper? 2021-12-29
  • On paraphrasing 2021-12-23
  • United Nations SDG Publishers Compact 2021-12-20

Newsletter Subscription

Subscribe to the journal newsletter and receive the latest news and updates

©